Stock 0P3C KAROLINSKA DEVELOPMENT AB
Add to a list
To use this feature you must be a member
Log inSign up

News Karolinska Development AB London S.E.

Equities

0P3C

SE0002190926

Market Closed - London S.E.
Other stock markets
 10:34:22 2022-09-06 am EDT 		5-day change 1st Jan Change
2.403 SEK +48.79% Intraday chart for Karolinska Development AB +55.67% +42.47%
Jul. 10 Umecrine Cognition AB announced that it has received SEK 28.3 million in funding from Ribbskottet AB, AB Ility AB, Karolinska Development AB and other investors CI
May. 28 Karolinska Development Targets 10% Stake in Boost Pharma MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Karolinska Development : portfolio company PharmNovo receives EUR 17.5 million from the innovation program EIC Accelerator
PU
Karolinska Development’s portfolio company PharmNovo receives EUR 17.5 million from the innovation program EIC Accelerator
GL
Karolinska Development : portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone
PU
Karolinska Development’s portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone
GL
Umecrine Cognition AB announced that it has received SEK 28.3 million in funding from Ribbskottet AB, AB Ility AB, Karolinska Development AB and other investors
CI
Karolinska Development : portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection
PU
Karolinska Development’s portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection
GL
Karolinska Development Targets 10% Stake in Boost Pharma
MT
Karolinska Development invests in BOOST Pharma, expanding its portfolio
GL
Boost Pharma Aps announced that it expects to receive funding from Industrifonden, Karolinska Development AB
CI
Karolinska Development : Annual General Meeting 2024
PU
Karolinska Development’s Annual General Meeting 2024
GL
Karolinska Development AB Appoints Hans Wigzell as Director and as Chairman
CI
Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC
GL
Interim Report - January-March 2024
GL
Karolinska Development AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Notice of Annual General Meeting in Karolinska Development AB (publ)
GL
Karolinska Development AB Announces That Björn Cochlovius Has Declined Re-Election
CI
Karolinska Development : portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC
PU
Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KDEV Stock
  4. 0P3C Stock
  5. News Karolinska Development AB